Allgens Medical Technology CO., LTD. (SHA:688613)
China · Delayed Price · Currency is CNY 16.03
+0.24 (1.52%)
Jun 12, 2026, 3:00 PM CST
SHA:688613 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 229.96 | 223.74 | 200.43 | 218.43 | 240.28 | 234.15 |
Other Revenue | - | - | 5.6 | 8.05 | 5.02 | 1.91 |
| 229.96 | 223.74 | 206.03 | 226.48 | 245.31 | 236.06 | |
Revenue Growth (YoY) | 14.33% | 8.59% | -9.03% | -7.68% | 3.91% | 28.46% |
Cost of Revenue | 72.45 | 70.12 | 59.4 | 39.24 | 40.79 | 35.62 |
Gross Profit | 157.51 | 153.62 | 146.63 | 187.24 | 204.51 | 200.44 |
Selling, General & Admin | 114.63 | 116.44 | 123.6 | 122.04 | 69.95 | 53.35 |
Research & Development | 43.11 | 39.25 | 38.77 | 45.5 | 57.46 | 33.23 |
Other Operating Expenses | 1.72 | 1.72 | 3.57 | 2.58 | 2.58 | 3.09 |
Operating Expenses | 159.45 | 157.41 | 174.08 | 171.22 | 130.6 | 90.16 |
Operating Income | -1.95 | -3.79 | -27.44 | 16.02 | 73.91 | 110.28 |
Interest Expense | - | - | -2.95 | -3.13 | -1.87 | -3.42 |
Interest & Investment Income | 0.38 | 0.12 | 15.06 | 6.18 | 5.62 | 4.28 |
Earnings From Equity Investments | - | - | - | - | - | 0.53 |
Currency Exchange Gain (Loss) | - | - | -0.13 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | 2.6 | 2.6 | -1.13 | -0.34 | 0.05 | -0.07 |
EBT Excluding Unusual Items | 1.03 | -1.07 | -16.59 | 18.73 | 77.72 | 111.61 |
Gain (Loss) on Sale of Investments | 12.58 | 13.05 | 6.35 | 15.1 | 10.2 | 14.39 |
Gain (Loss) on Sale of Assets | 0.17 | 0.46 | 0.64 | -0.59 | -0.32 | - |
Asset Writedown | -0.16 | -0.16 | - | - | - | -0.01 |
Other Unusual Items | - | - | 0.66 | 15.85 | 8.61 | 6.07 |
Pretax Income | 13.62 | 12.29 | -8.94 | 49.09 | 96.2 | 132.05 |
Income Tax Expense | 3.41 | 2.79 | 8.2 | -3.87 | 4.5 | 13.98 |
Earnings From Continuing Operations | 10.21 | 9.5 | -17.14 | 52.97 | 91.7 | 118.07 |
Minority Interest in Earnings | 4 | 4.34 | 4.48 | 1.27 | 3.52 | 2.71 |
Net Income | 14.21 | 13.84 | -12.66 | 54.23 | 95.22 | 120.78 |
Net Income to Common | 14.21 | 13.84 | -12.66 | 54.23 | 95.22 | 120.78 |
Net Income Growth | - | - | - | -43.04% | -21.17% | 35.80% |
Shares Outstanding (Basic) | 148 | 138 | 141 | 132 | 134 | 120 |
Shares Outstanding (Diluted) | 148 | 138 | 141 | 132 | 134 | 120 |
Shares Change (YoY) | 11.81% | -1.63% | 6.36% | -1.37% | 12.14% | 19.66% |
EPS (Basic) | 0.10 | 0.10 | -0.09 | 0.41 | 0.71 | 1.01 |
EPS (Diluted) | 0.10 | 0.10 | -0.09 | 0.41 | 0.71 | 1.01 |
EPS Growth | - | - | - | -42.25% | -29.70% | 13.48% |
Free Cash Flow | -5.25 | 10.56 | -33.03 | 29.78 | 56.63 | 68.54 |
Free Cash Flow Per Share | -0.04 | 0.08 | -0.23 | 0.23 | 0.42 | 0.57 |
Dividend Per Share | - | - | - | 0.060 | 0.107 | 0.272 |
Dividend Growth | - | - | - | -43.92% | -60.66% | - |
Gross Margin | 68.49% | 68.66% | 71.17% | 82.67% | 83.37% | 84.91% |
Operating Margin | -0.85% | -1.70% | -13.32% | 7.07% | 30.13% | 46.72% |
Profit Margin | 6.18% | 6.19% | -6.15% | 23.95% | 38.82% | 51.17% |
Free Cash Flow Margin | -2.28% | 4.72% | -16.03% | 13.15% | 23.09% | 29.04% |
EBITDA | 19.07 | 16.43 | -10.43 | 30.81 | 88.11 | 121.03 |
EBITDA Margin | 8.29% | 7.34% | -5.06% | 13.61% | 35.92% | 51.27% |
D&A For EBITDA | 21.02 | 20.22 | 17.02 | 14.79 | 14.2 | 10.75 |
EBIT | -1.95 | -3.79 | -27.44 | 16.02 | 73.91 | 110.28 |
EBIT Margin | -0.85% | -1.70% | -13.32% | 7.07% | 30.13% | 46.72% |
Effective Tax Rate | 25.00% | 22.67% | - | - | 4.68% | 10.59% |
Revenue as Reported | 6.22 | - | 206.03 | 226.48 | 245.31 | 236.06 |